Anti-HER2 antibody

Anti-HER2 antibody

Anti-HER2 antibodies are antibody drugs that target HER2 (Human Epidermal Growth Factor Receptor 2). HER2 is a receptor tyrosine kinase belonging to the EGFR family, responsible for signal transduction involved in cell proliferation and survival. Anti-HER2 antibodies,To suppress tumor cell proliferation signals mediated by HER2It exerts an anti-tumor effect and is widely used for the treatment of HER2-positive breast cancer and gastric cancer. As a representative antibody drug for the development of molecular targeted therapy, it holds an important position in both drug discovery and clinical practice.

Representative examples of anti-HER2 antibodies

Trastuzumab (Herceptin)

Trastuzumab (Herceptin) isRepresentative anti-HER2 antibodies that bind to HER2It inhibits HER2 signaling, suppresses tumor cell proliferation, and exerts an anti-tumor effect through ADCC (antibody-dependent cell-mediated cytotoxicity) activity. It is a representative drug in the development of anti-HER2 antibodies, having established the efficacy of anti-HER2 therapy.

Pertuzumab (Perjeta)

Pertuzumab (Perjeta) is a HER2-Anti-HER2 antibody that inhibits dimer formationBoth inhibit the HER2 signal, but their binding sites and mechanisms of action differ from trastuzumab. Combining both drugs is expected to provide complementary anti-tumor effects and is used as a representative combination therapy for HER2-positive breast cancer and other conditions.

Margenza

Margenza isFc-engineered antibodyIt was developed as a next-generation anti-HER2 antibody aiming to enhance anti-tumor effects by optimizing interaction with Fc receptors to increase ADCC activity. It is one of the representative antibody drugs developed using antibody engineering technology.

Key challenges in developing anti-HER2 antibodies

Addressing HER2 Expression Levels and Tumor Heterogeneity

The efficacy of anti-HER2 antibodies varies greatly depending on the amount of HER2 expression,HER2 expression is not uniform within the tumorThis affects therapeutic efficacy. In recent years, a new concept called HER2-low has also attracted attention, and for appropriate patient selection, validation using patient-derived models and highly accurate pathological evaluation are important.

Overcoming drug resistance

Regarding anti-HER2 antibodies,Dependence on pathways other than HER2 signaling or activation of the PI3K/AKT pathwayDecreased HER2 expression and antibody internalization are factors contributing to drug resistance. To overcome these resistance mechanisms, it is important to advance the development of new therapeutic strategies and next-generation anti-HER2 antibodies through efficacy evaluation using resistance models.

How to predict drug efficacy and safety in humans

Regarding anti-HER2 antibodies,Immune functions such as ADCC are also involved in the drug efficacy.Therefore, evaluating drug efficacy, including the immune system, is important. Additionally, on-target toxicities, such as cardiotoxicity due to action on HER2-expressing normal tissues, must also be considered. It is necessary to comprehensively evaluate drug efficacy and safety by utilizing disease models with high human translatability.

Non-clinical evaluation required for anti-HER2 antibody development

To construct a pathological model that can accurately reproduce HER2 expression

In the evaluation of anti-HER2 antibodies, in addition to cell lines that mimic HER2 expression levels, HER2-low models, PDX, and organoids are used.Combine multiple disease modelsis important. Because they each have different characteristics, it leads to improved drug efficacy evaluation and human translatability that reflect HER2 expression and tumor heterogeneity.

Evaluate the effect on the target and immune activity in a multifaceted way.

Regarding the evaluation of anti-HER2 antibodies,Evaluate target engagement and ADCC activity multifacetedThis is important. By combining HER2 expression analysis, flow cytometry, digital pathology, and biomarker analysis, and integrating them with pharmacodynamic studies, we can comprehensively evaluate target engagement and immune activation.

Integrate pharmacokinetics and intratumoral distribution for evaluation.

Regarding anti-HER2 antibodies,Integrate and evaluate PK evaluation and intratumoral distribution analysisIt is important. By analyzing antibody pharmacokinetics and tissue infiltration, and combining PK/PD assessment with efficacy evaluation, the relationship between target tissue penetration and therapeutic effect can be comprehensively understood.

Evaluate safety from the early stages of development

Regarding anti-HER2 antibodies,Comprehensively evaluate safety from early stages of developmentThis is important. In addition to cardiotoxicity, anti-drug antibodies (ADAs), and immunotoxicity, safety assessments such as hERG and long-term safety will be considered as needed. By establishing an evaluation strategy tailored to the modality's characteristics, it will lead to a smooth transition to clinical trials.

Key points when choosing a contract research organization (CRO) for non-clinical studies

In the development of anti-HER2 antibodies, selecting a CRO that can consistently conduct everything from pathological model construction to efficacy and safety evaluation is crucial. Development is becoming more sophisticated with the inclusion of HER2-low and new modalities, and strategic non-clinical testing is the key to success. Leveraging CROs with extensive evaluation experience contributes to improved development efficiency and clinical predictability.